Results 141 to 150 of about 10,093 (182)
Heterogeneity in clinical appearance of chronic spontaneous urticaria: A cross-sectional analysis of a retrospective cohort. [PDF]
World Allergy Organ JToprak İD +9 more
europepmc +1 more source
Immunological Basis of Chronic Spontaneous Urticaria: Immunoglobulin E and Beyond. [PDF]
Yonsei Med JRhyou HI, Nam YH, Park JW, Park HS.
europepmc +1 more source
Differential MicroRNA Expression in Chronic Spontaneous Urticaria in Relation to Treatment Response. [PDF]
Allergy Asthma Immunol ResLee Y +6 more
europepmc +1 more source
Chronic spontaneous urticaria as an autoimmune feature in common variable immunodeficiency. [PDF]
J Allergy Clin Immunol GlobKorevaar ECA, Karim AF, Dalm VASH.
europepmc +1 more source
Treatments and Targets to Achieve Disease Control in Chronic Spontaneous Urticaria: Current and Emerging Therapeutic Options. [PDF]
J Inflamm ResØstergaard CES, Thomsen SF, Zhang DG.
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Drugs, 2001
* Omalizumab is a recombinant humanised monoclonal antibody which specifically binds to the C epsilon3 domain of immunoglobulin (Ig) E, the site of high-affinity IgE receptor binding. * Improvements in asthma symptoms and health-related quality-of-life, and a significant reduction in the frequency of asthma exacerbations were seen in allergic asthmatic
S, Easthope, B, Jarvis
openaire +3 more sources
* Omalizumab is a recombinant humanised monoclonal antibody which specifically binds to the C epsilon3 domain of immunoglobulin (Ig) E, the site of high-affinity IgE receptor binding. * Improvements in asthma symptoms and health-related quality-of-life, and a significant reduction in the frequency of asthma exacerbations were seen in allergic asthmatic
S, Easthope, B, Jarvis
openaire +3 more sources
New England Journal of Medicine, 2006
A 16-year-old boy with a history of severe persistent asthma despite treatment with inhaled corticosteroids presents for evaluation. Treatment with omalizumab, a monoclonal anti-IgE antibody, is recommended. This agent has been found to reduce the frequency of exacerbations of asthma in clinical trials.
Robert C, Strunk, Gordon R, Bloomberg
openaire +2 more sources
A 16-year-old boy with a history of severe persistent asthma despite treatment with inhaled corticosteroids presents for evaluation. Treatment with omalizumab, a monoclonal anti-IgE antibody, is recommended. This agent has been found to reduce the frequency of exacerbations of asthma in clinical trials.
Robert C, Strunk, Gordon R, Bloomberg
openaire +2 more sources